Hypoparathyroidism Market Report 2026

Hypoparathyroidism Market Overview

• Hypoparathyroidism market size has reached to $1.03 billion in 2025 • Expected to grow to $1.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.2% • Growth Driver: Increasing Cases Of Thyroid Cancer Fueling The Growth Of The Market Due To Rise In Surgical Interventions And Postoperative Complications • Market Trend: Transcon Platform Enables Long-Acting Prodrugs For Sustained Hormone Release • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hypoparathyroidism Market?

Hypoparathyroidism is a rare endocrine disorder where the parathyroid glands produce insufficient amounts of parathyroid hormone (PTH), which leads to low calcium and high phosphorus levels in the blood. The primary purpose of parathyroid hormone (PTH) is to regulate and maintain stable levels of calcium and phosphorus, which are essential for nerve, muscle, and bone function. Hypoparathyroidism can result from surgical removal or damage to the parathyroid glands, autoimmune diseases, genetic conditions, or, rarely, idiopathic causes. The main types of treatments in hypoparathyroidism are hormone replacement therapy and adjunctive therapies. Hormone replacement therapy (HRT) refers to the medical treatment in which hormones are given to replace or supplement those that the body is no longer producing sufficiently. These are used for various types, including hormone replacement therapy, calcium and vitamin d supplements and emerging therapies. The various route of administration include oral and parenteral that are distributed through hospital pharmacy, retail pharmacy and online pharmacy, serving various end users such as hospitals, specialty clinics and homecare settings.

What Is The Hypoparathyroidism Market Growth Forecast?

The hypoparathyroidism market size is expected to see strong growth in the next few years. It will grow to $1.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to advancements in recombinant therapies, improved rare disease diagnosis, patient adherence programs, specialty clinic expansion, precision endocrinology adoption. Major trends in the forecast period include increased diagnosis of rare endocrine disorders, growing use of recombinant parathyroid hormones, expansion of long-term calcium management therapies, improved awareness of post-surgical complications, development of adjunctive supportive treatments.

Global Hypoparathyroidism Market Segmentation

1) By Treatment: Hormone Replacement Therapy, Adjunctive Therapies 2) By Type: Hormone Replacement Therapy, Calcium And Vitamin D Supplements, Emerging Therapies 3) By Route Of Administration: Oral, Parenteral 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 5) By End User: Hospitals, Specialty Clinics, Homecare Settings Subsegments: 1) By Hormone Replacement Therapy: Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues, Calcimimetics, Calcium And Vitamin D Supplements 2) By Adjunctive Therapies: Magnesium Supplements, Phosphate Binders, Other Supportive Therapies

What Is The Driver Of The Hypoparathyroidism Market?

The increasing cases of thyroid cancer are expected to propel the growth of the hypoparathyroidism market going forward. Thyroid cancer refers to a type of cancer where abnormal cells grow in the thyroid gland, often forming a lump in the neck. The increasing cases of thyroid cancer are due to advancements in diagnostic imaging technologies, as they enable early and more frequent detection of small, asymptomatic thyroid nodules. Thyroid cancer accelerates hypoparathyroidism by increasing the need for thyroid surgeries, which can inadvertently damage the parathyroid glands. This leads to calcium imbalance and chronic hormone deficiency, driving demand for long-term disease management solutions. For instance, in May 2024, according to the American Cancer Society, a US-based non-profit organization, the number of new thyroid cancer cases reached 44,020 in 2025, up from 43,720 in 2023. Therefore, the increasing cases of thyroid cancer are driving the growth of the hypoparathyroidism industry.

Key Players In The Global Hypoparathyroidism Market

Major companies operating in the hypoparathyroidism market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc , Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited , Lupin Limited, Torrent Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., BridgeBio Pharma Inc., Ascendis Pharma A/S, Extend Biosciences Inc., Entera Bio Ltd.

Global Hypoparathyroidism Market Trends and Insights

Major companies operating in the hypoparathyroidism market are focusing on developing technologically advanced products, such as transition technology-based products, to enhance treatment efficacy and improve patient outcomes. TransCon technology-based products are therapeutics developed using TransCon (Transient Conjugation) technology, a proprietary platform designed to optimize drug delivery. For instance, in January 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched YORVIPATH (palopegteriparatide), its second TransCon technology-based product, in Germany and Austria for the treatment of adults with chronic hypoparathyroidism. YORVIPATH is a once-daily prodrug of parathyroid hormone (PTH 1-34) designed to maintain physiological PTH levels over 24 hours, addressing the underlying hormone deficiency in chronic hypoparathyroidism.

What Are Latest Mergers And Acquisitions In The Hypoparathyroidism Market?

In July 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Amolyt Pharma SAS for an undisclosed amount. With this acquisition, AstraZeneca aims to strengthen its rare disease portfolio, particularly in the area of endocrine diseases, leveraging Amolyt Pharma’s innovative pipeline and clinical-stage therapies. Amolyt Pharma SAS is a France-based biotechnology company developing eneboparatide, a long-acting parathyroid hormone analog for treating hypoparathyroidism.

Regional Insights

North America was the largest region in the hypoparathyroidism market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hypoparathyroidism Market?

The hypoparathyroidism market consists of revenues earned by entities by providing services such as diagnostic testing, patient monitoring, telemedicine consultations, and specialized care for chronic disease management and education. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypoparathyroidism market also includes sales of phosphate binders, and medical devices or diagnostic kits used for monitoring calcium, phosphorus, and parathyroid Hormone levels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hypoparathyroidism Market Report 2026?

The hypoparathyroidism market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hypoparathyroidism industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.